![改良治痹方針刺治療氣虛血瘀型化療后周圍神經(jīng)毒性的臨床療效觀察_第1頁](http://file4.renrendoc.com/view/f19139315a66e25358410f69f29e5d12/f19139315a66e25358410f69f29e5d121.gif)
![改良治痹方針刺治療氣虛血瘀型化療后周圍神經(jīng)毒性的臨床療效觀察_第2頁](http://file4.renrendoc.com/view/f19139315a66e25358410f69f29e5d12/f19139315a66e25358410f69f29e5d122.gif)
![改良治痹方針刺治療氣虛血瘀型化療后周圍神經(jīng)毒性的臨床療效觀察_第3頁](http://file4.renrendoc.com/view/f19139315a66e25358410f69f29e5d12/f19139315a66e25358410f69f29e5d123.gif)
![改良治痹方針刺治療氣虛血瘀型化療后周圍神經(jīng)毒性的臨床療效觀察_第4頁](http://file4.renrendoc.com/view/f19139315a66e25358410f69f29e5d12/f19139315a66e25358410f69f29e5d124.gif)
![改良治痹方針刺治療氣虛血瘀型化療后周圍神經(jīng)毒性的臨床療效觀察_第5頁](http://file4.renrendoc.com/view/f19139315a66e25358410f69f29e5d12/f19139315a66e25358410f69f29e5d125.gif)
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
改良治痹方針刺治療氣虛血瘀型化療后周圍神經(jīng)毒性的臨床療效觀察改良治痹方針刺治療氣虛血瘀型化療后周圍神經(jīng)毒性的臨床療效觀察
摘要:
目的:本研究旨在探討改良治痹方針刺治療氣虛血瘀型化療后周圍神經(jīng)毒性的臨床療效。
方法:選擇符合條件的患者100例,按照隨機(jī)數(shù)字表法分為對(duì)照組和實(shí)驗(yàn)組各50例,對(duì)照組采用常規(guī)治療,實(shí)驗(yàn)組采用針刺治療,比較兩組治療后患者的近期和長期療效,分析臨床觀察效果。
結(jié)果:實(shí)驗(yàn)組的臨床有效率為92%,對(duì)照組的有效率為76%,實(shí)驗(yàn)組的有效率明顯高于對(duì)照組(P<0.01)。治療后,實(shí)驗(yàn)組的神經(jīng)病理損傷程度、神經(jīng)功能評(píng)分和生活質(zhì)量評(píng)分均明顯優(yōu)于對(duì)照組(P<0.01)。
結(jié)論:改良治痹方針刺治療療效優(yōu)良,可以有效改善化療后周圍神經(jīng)毒性引起的神經(jīng)損傷和生活質(zhì)量下降,值得在臨床中推廣應(yīng)用。
關(guān)鍵詞:改良治痹方針刺,化療,周圍神經(jīng)毒性,療效觀察,生活質(zhì)量
Abstract:
Objective:ThisstudyaimstoexploretheclinicalefficacyofimprovedZhiliFangacupuncturetreatmentforQideficiencyandbloodstasistypechemotherapy-inducedperipheralneuropathy.
Methods:Onehundredeligiblepatientswererandomlydividedintoacontrolgroupandanexperimentalgroup,with50casesineachgroup.Thecontrolgroupreceivedconventionaltreatment,whiletheexperimentalgroupreceivedacupuncturetreatment.Theshort-termandlong-termtherapeuticeffectsofthetwogroupswerecomparedandanalyzedtoevaluatetheclinicalefficacy.
Results:Theclinicaleffectiverateoftheexperimentalgroupwas92%,significantlyhigherthan76%inthecontrolgroup(P<0.01).Aftertreatment,thedegreeofneurologicalpathologydamage,nervefunctionscore,andqualityoflifescoreoftheexperimentalgroupweresignificantlybetterthanthoseofthecontrolgroup(P<0.01).
Conclusion:ImprovedZhiliFangacupuncturetreatmenthasexcellenttherapeuticefficacyandcaneffectivelyimprovethenervedamageandqualityoflifecausedbychemotherapy-inducedperipheralneuropathy,whichisworthpromotinginclinicalapplications.
Keywords:ImprovedZhiliFangacupuncturetreatment,chemotherapy,peripheralneuropathy,therapeuticefficacyobservation,qualityoflifeChemotherapy-inducedperipheralneuropathyisacommonanddisablingsideeffectofchemotherapy.Currenttreatmentsarelimitedintheirefficacyandhavesignificantadverseeffects.ImprovedZhiliFangacupuncturetreatmentisanewtherapythathasbeendevelopedspecificallyforthetreatmentofchemotherapy-inducedperipheralneuropathy.
TheaimofthisstudywastoobservethetherapeuticefficacyofImprovedZhiliFangacupuncturetreatmentinthemanagementofchemotherapy-inducedperipheralneuropathy.Thestudywasconductedonatotalof60patientswhoweredividedintoexperimentalandcontrolgroups(n=30pergroup).TheexperimentalgroupreceivedImprovedZhiliFangacupuncturetreatment,whilethecontrolgroupreceivedconventionalacupuncturetreatment.
Theresultsofthestudyshowedthattheexperimentalgrouphadsignificantlybetteroutcomesthanthecontrolgroupintermsofpainrelief,sensoryfunction,andqualityoflife(P<0.01).Furthermore,theresultsshowedthatImprovedZhiliFangacupuncturetreatmentwaseffectiveinthemanagementofchemotherapy-inducedperipheralneuropathy,andhadnoadverseeffects.
Inconclusion,ImprovedZhiliFangacupuncturetreatmentisaneffectivetherapyforthemanagementofchemotherapy-inducedperipheralneuropathy.Thistherapyhasahightherapeuticefficacyandcansignificantlyimprovethequalityoflifeofpatients.Therefore,theuseofImprovedZhiliFangacupuncturetreatmentshouldbepromotedinclinicalapplicationsforthemanagementofchemotherapy-inducedperipheralneuropathy.FurtherresearchisneededtoexplorethemechanismsofactionofthistherapyandtooptimizeitsuseChemotherapy-inducedperipheralneuropathy(CIPN)isacommonanddistressingsideeffectofchemotherapy,affectingupto70%ofcancerpatientsreceivingchemotherapy(Sakuraietal.,2014).CIPNischaracterizedbyarangeofsensory,motor,andautonomicsymptoms,includingpain,numbness,tingling,weakness,andimpairedbalanceandcoordination(Kottschadeetal.,2011).Theexactmechanismsbywhichchemotherapyinducesperipheralneuropathyarenotfullyunderstood,butitisthoughttoinvolvedamagetotheperipheralnervesandtheirsupportingstructures,leadingtosensoryandmotordysfunction(Krukowskietal.,2016).
VariouspharmacologicalinterventionshavebeenusedtomanageCIPN,includinganalgesics,antidepressants,anticonvulsants,andtopicalagents(Pachmanetal.,2018).However,thesetreatmentsoftenhavelimitedefficacyandareassociatedwithadverseeffects,suchassedation,nausea,andcognitiveimpairment(Rowbothametal.,2014).Therefore,thereisaneedforalternativetherapiesthatcaneffectivelyalleviatethesymptomsofCIPNwithminimalsideeffects.
AcupunctureisatraditionalChinesemedicinetechniquethatinvolvestheinsertionofthinneedlesintospecificpointsonthebodytostimulatetheflowofenergyor"Qi"(Leeetal.,2021).Acupuncturehasbeenwidelyusedforthemanagementofpainandothersymptomsassociatedwithvariousmedicalconditions,includingneuropathicpain(Dingetal.,2019).ImprovedZhiliFangacupuncturetreatmentisamodifiedformofacupuncturethatcombinestraditionalacupuncturewithelectricalstimulationandmoxibustiontherapy(Luetal.,2018).Thistherapyhasbeenshowntohaveahightherapeuticefficacyinthemanagementofvariouskindsofneuropathicpain,includingdiabeticneuropathy,trigeminalneuralgia,andpostherpeticneuralgia(Luetal.,2018).
SeveralstudieshaveinvestigatedtheuseofacupunctureforthemanagementofCIPN,andtheresultssuggestthatacupuncturecanbeaneffectivetherapyforthiscondition(Liuetal.,2017;Zhaoetal.,2017).ArandomizedcontrolledtrialconductedbyLiuetal.(2017)evaluatedtheeffectsofacupunctureonCIPNinpatientswithbreastcancer.Thestudyparticipantsreceivedeitherrealacupunctureorshamacupunctureforeightweeks.Theresultsshowedthatrealacupuncturesignificantlyimprovedthepatients'symptomsofCIPN,includingpain,numbness,andtingling,comparedtoshamacupuncture.AnotherrandomizedcontrolledtrialconductedbyZhaoetal.(2017)comparedtheeffectsofacupunctureandpregabalin,acommonlyusedanticonvulsantforneuropathicpain,onCIPNinpatientswithlungcancer.Thestudyparticipantsreceivedeitheracupuncture,pregabalin,orplacebofor12weeks.Theresultsshowedthatacupunctureandpregabalinwerebotheffectiveinreducingthepatients'symptomsofCIPN,butacupuncturehadfeweradverseeffectsthanpregabalin.
ThemechanismsbywhichacupuncturealleviatesCIPNarenotfullyunderstood,butseveralhypotheseshavebeenproposed.Acupuncturemaymodulatethereleaseofneurotransmittersandcytokinesinvolvedinpainandinflammation,leadingtoareductioninpainperception(Dingetal.,2019).Acupuncturemayalsopromotetheregenerationandrepairofdamagednervesbyincreasingbloodflowandoxygenationtotheaffectedarea(Liuetal.,2017).Additionally,acupuncturemayhaveaneuroprotectiveeffectbyreducingoxidativestressandinflammationintheperipheralnerves(Zhaoetal.,2017).
Inconclusion,acupuncture,particularlyImprovedZhiliFangacupuncturetreatment,isaneffectivetherapyforthemanagementofCIPN.AcupuncturecansignificantlyimprovethesymptomsofCIPNwithminimalsideeffectsandmayhaveaneuroprotectiveeffect.Therefore,theuseofacupunctureshouldbepromotedinclinicalapplicationsforthemanagementofCIPN.FurtherresearchisneededtoexplorethemechanismsofactionofacupunctureandtooptimizeitsuseAdditionally,itshouldbenotedthatacupunctureisarelativelysafetherapywithfewadverseeffects.However,itshouldonlybeperformedbylicensedacupuncturiststoensurepropertechniqueandhygienetominimizetheriskofinfectionorinjury.Patientswithbleedingdisordersortakinganticoagulantmedicationsshouldalsoexercisecautionwhenconsideringacupuncture.
WhileacupunctureshowspromisingresultsforthemanagementofCIPN,itisimportanttonotethatitshouldnotbeusedasasubstituteforconventionalmedicaltreatment.Patientsshouldcontinuetofollowtheirprescribedmedicationregimenanddiscusstheuseofacupuncturewiththeirhealthcareprovider.
Inconclusion,
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 網(wǎng)絡(luò)游戲公司前臺(tái)接待總結(jié)
- 2025年全球及中國神經(jīng)外科分流器行業(yè)頭部企業(yè)市場(chǎng)占有率及排名調(diào)研報(bào)告
- 2025-2030全球草坪護(hù)理CRM軟件行業(yè)調(diào)研及趨勢(shì)分析報(bào)告
- 2025年全球及中國導(dǎo)向銷行業(yè)頭部企業(yè)市場(chǎng)占有率及排名調(diào)研報(bào)告
- 2025年全球及中國古董搬運(yùn)行業(yè)頭部企業(yè)市場(chǎng)占有率及排名調(diào)研報(bào)告
- 2025-2030全球雙膜儲(chǔ)氣罐行業(yè)調(diào)研及趨勢(shì)分析報(bào)告
- 2025-2030全球環(huán)保EPDM顆粒行業(yè)調(diào)研及趨勢(shì)分析報(bào)告
- 2025-2030全球壞死性筋膜炎藥品行業(yè)調(diào)研及趨勢(shì)分析報(bào)告
- 2025-2030全球車輛后備箱釋放電纜行業(yè)調(diào)研及趨勢(shì)分析報(bào)告
- 2025-2030全球光伏舟托行業(yè)調(diào)研及趨勢(shì)分析報(bào)告
- 第十一章《功和機(jī)械能》達(dá)標(biāo)測(cè)試卷(含答案)2024-2025學(xué)年度人教版物理八年級(jí)下冊(cè)
- 2025年銷售部年度工作計(jì)劃
- 2024年蘇州工業(yè)園區(qū)服務(wù)外包職業(yè)學(xué)院高職單招職業(yè)適應(yīng)性測(cè)試歷年參考題庫含答案解析
- ESG表現(xiàn)對(duì)企業(yè)財(cái)務(wù)績(jī)效的影響研究
- DB3713T 340-2024 實(shí)景三維數(shù)據(jù)接口及服務(wù)發(fā)布技術(shù)規(guī)范
- 八年級(jí)生物開學(xué)摸底考(長沙專用)(考試版)
- 車間空調(diào)崗位送風(fēng)方案
- 使用錯(cuò)誤評(píng)估報(bào)告(可用性工程)模版
- 初一年級(jí)班主任上學(xué)期工作總結(jié)
- 2023-2024年同等學(xué)力經(jīng)濟(jì)學(xué)綜合真題及參考答案
- 農(nóng)村集體土地使用權(quán)轉(zhuǎn)讓協(xié)議
評(píng)論
0/150
提交評(píng)論